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Abstract
Background: Prediction of absolute risk of cardiovascular diseases (CVDs) has important clinical and public
health significance, but the predictive ability of the available tools has not yet been tested in the rural
Bangladeshi population. The present study was undertaken to test the hypothesis that both laboratory-based
(Framingham equation and WHO/ISH laboratory-based charts) and non-laboratory-based tools may be used
to predict CVDs on a short-term basis. Methods: Data from a case-cohort study (52989 cohort and 439 sub-
cohort participants), conducted on a rural Bangladeshi population, were analysed using modified Cox PH
model with a maximum follow-up of 2.5 years. The outcome variable, coronary heart diseases (CHDs), was
assessed in 2014 using electrocardiography, and it was used as a surrogate marker for CVDs in Bangladesh.
The predictive power of the models was assessed by calculating C-statistics and generating ROC curves with
other measures of diagnostic tests. Results: All the models showed high negative prediction values (NPVs, 84
% to 92 %) and these did not differ between models or gender. The sensitivity of the models substantially
changed based on the risk prediction thresholds (between 5-30 %); however, the NPVs and PPVs were
relatively stable at various threshold levels. Hypertension and dyslipidaemia were significantly associated with
CHD outcome in males and ABSI (a body shape index) in females. All models showed similar C-statistics
(0.611-0.685, in both genders). Overall, the non-laboratory-based model showed better performance (0.685)
in women but equal performance in men. Conclusions: Existing CVD risk prediction tools may identify
future CHD cases with fairly good confidence on a short-term basis. The non-laboratory-based tool, using
ABSI as a predictor, may provide better predictive accuracy among women.
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Background: Prediction of absolute risk of cardiovascular diseases (CVDs) has important clinical and public health
significance, but the predictive ability of the available tools has not yet been tested in the rural Bangladeshi
population. The present study was undertaken to test the hypothesis that both laboratory-based (Framingham
equation and WHO/ISH laboratory-based charts) and non-laboratory-based tools may be used to predict CVDs
on a short-term basis.
Methods: Data from a case-cohort study (52989 cohort and 439 sub-cohort participants), conducted on a rural
Bangladeshi population, were analysed using modified Cox PH model with a maximum follow-up of 2.5 years.
The outcome variable, coronary heart diseases (CHDs), was assessed in 2014 using electrocardiography, and it
was used as a surrogate marker for CVDs in Bangladesh. The predictive power of the models was assessed by
calculating C-statistics and generating ROC curves with other measures of diagnostic tests.
Results: All the models showed high negative prediction values (NPVs, 84 % to 92 %) and these did not differ
between models or gender. The sensitivity of the models substantially changed based on the risk prediction
thresholds (between 5–30 %); however, the NPVs and PPVs were relatively stable at various threshold levels.
Hypertension and dyslipidaemia were significantly associated with CHD outcome in males and ABSI (a body
shape index) in females. All models showed similar C-statistics (0.611–0.685, in both genders). Overall, the
non-laboratory-based model showed better performance (0.685) in women but equal performance in men.
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Background
Prediction of risk can greatly help in the management
and prevention of cardiovascular diseases (CVDs) as well
as in designing long-term policies and programs in this
sector. It is now well-acknowledged that absolute risk
assessment, based on the combined effect of multiple
risk factors, yields better accuracy compared to the indi-
vidual risk factor based approach in predicting CVD
events [1, 2]. Absolute risk factor profiling was originally
proposed in the landmark Framingham study [3, 4] and
most of the later prediction tools [5–7] are adapted from
the original one. Another important development in this
area is the WHO/ISH 10-years CVD risk assessment
chart proposed in 2007 [8] which was designed as a tool
suitable for application in low resource settings.
Framingham scoring and its adaptations have been val-
idated through various prospective and longitudinal
studies [9–11], but those have been done almost solely
in the context of developed societies. In contrast, a num-
ber of studies have been conducted with the WHO/ISH
tool in developing countries [12–14], but those are al-
most exclusively cross-sectional studies and validations
by prospective and longitudinal studies are lacking.
In recent years we have initiated a cohort in a periph-
erally located rural Bangladeshi population from which
baseline data on individual and absolute CVD risk have
been reported previously [15]. In the present communi-
cation, two laboratory and two non-laboratory-based
models of absolute CVD prediction tools (based on
adaptation of Framingham risk score, ‘with’ or ‘without
cholesterol’ version of WHO/ISH tool, and a tool with
the same risk factors as Framingham but with laboratory
variables replaced by the best anthropometric predictive
risk factor for CHD from this study, have been tested for
a ‘proof of the concept’ on a short-term (2.5 years) basis.
The outcome variable in this study is electrocardio-
graphic evidence of coronary heart disease (CHD) which
has been considered as a surrogate marker of CVDs in
general [16–18]. The advantage of using ECG as a tool
is its objectivity to avoid recall bias in this underdevel-
oped rural population with poor socioeconomic, educa-
tional and disease awareness status. Although 2.5 years
is a limited period for risk predictivity, to the best of our
knowledge, no study has yet been done with any tool on
such a short-term basis and thus, the findings may be of
interest for practicing clinicians.
Methods
The original cohort was initiated in 2008 under the
‘BADAS-ORBIS Eye Care Project’. The cohort had
66,701 participants aged between 31–74 years in 2008.
In 2011-12, a screening program was conducted using a
questionnaire based tool developed as a part of the
‘WHO CVD risk management package for low- and
medium – resource settings’ and following the recom-
mendations of WHO [19]. From the remaining ‘screened
negative’ participants (n = 62,538), a sub-cohort were
recruited randomly. Initially 1000 participants were
approached; out of them 563 (56.3 %) agreed to take part
and provided data. The detailed description of the
program is available elsewhere [15]. Following the case-
cohort design with maximum 2.5 years of follow-up,
from July 2012 to December 2014, another screening
program was conducted using similar steps as in
September 2011 to March 2012. CHD-related abnorma-
lities were evidenced by ECG. In 2014, of the 63,708
eligible residents, 52,989 gave consent (participation rate
85.02 %) and 42 were ECG positive. In the sub-cohort
77.97 % (439/563) agreed, 18 were ECG positive and 27
did not complete all the biochemical tests of the study.
All the ECG positive and consented sub-cohort partic-
ipants, using a structured, pretested, interviewer admin-
istrated questionnaire, were interviewed to obtain
information on (i) socio-demographic characteristics, (ii)
three days dietary intake history including fruit and
vegetable intake [consumption assessed by a question
that inquired the number of serving (medium portions)
of any fruit or vegetable per day], (iii) smoking status in-
cluding type of smoking and/or smokeless tobacco use,
past smoking history; (iv) physical examination including
blood pressure measurements with an oscillometric de-
vice after at least 5 min of rest and blood biochemistry.
Height and weight were measured; body mass index
(BMI) (kg/m2), waist circumference (WC), hip circum-
ference (HC) and waist-hip-ratio (WHR) were calcu-
lated. ABSI was calculated as WC divided by BMI in
power of 2/3 multiplied by height in power of 1/2 (WC/
(BMI2/3 × height1/2)) [20].
Hypertension was categorized according to blood pres-
sure (BP) readings by JNC-V definitions [21]: optimal
(systolic, <120 mm Hg and diastolic, <80 mm Hg), nor-
mal blood pressure (systolic <120 to 129 mm Hg or dia-
stolic <80 to 84 mm Hg), high normal blood pressure
(systolic 130 to 139 mm Hg or diastolic 85 to 89 mm
Hg), hypertension stage I (systolic 140 to 159 mm Hg or
diastolic 90 to 99 mm Hg), and hypertension stage II–IV
(systolic ≥160 or diastolic ≥100 mm Hg). When systolic
and diastolic pressures fell into different categories, the
higher category was selected for the purpose of clas-
sification. Blood pressure categorization was made
dis regarding the use of anti-hypertension medication.
Diabetes mellitus (DM) was considered as fasting blood
glucose (FBG) ≥7.0 mmol/L and/or 2 h after 75-g oral
glucose solution ≥11.1 mmol/L and pre-DM followed by
the WHO guideline [22]. In addition, DM was defined
by the use of insulin or oral anti-diabetic medication(s).
Blood was drawn at the baseline examination after an
overnight fasting, and ethylene diamine tetraacetic acid
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(EDTA) plasma was used for all cholesterol, triglyceride
and HDL (mg/dl) measurements. All of them were
determined according to the enzymatic colorimetric
method, and LDL was estimated by Friedewald’s for-
mula. Study subjects were followed up over a 2.5-years
period for the development of CHD (includes angina
pectoris, recognized and unrecognized myocardial in-
farction, coronary insufficiency, and coronary heart
disease death). We collected binary information on
smoking (Smoker/non-smoker). Current regular smo-
king was defined as at least one cigarette per day or
smoked regularly during the previous 12 months.
We compared four risk prediction models: model 1:
the Framingham laboratory-based model; model 2:
‘With’ cholesterol versions and model 3: ‘Without’ chol-
esterol version of the World Health Organization/Inter-
national Society of Hypertension chart developed for
estimating CVD risk for the South-East Asian Region D,
and model 4: Non-laboratory-based model. We also
checked how well these models could predict various
levels of risks for cardiovascular events in the North
Bengal Non-Communicable Disease Program (NB-
NCDP) cohort. In model 1 we used the same risk factors
as in the Framingham model: sex, age (years), systolic
blood pressure (SBP; mm Hg), smoking status (past or
current vs never), total cholesterol (TC), High-density
lipoprotein (HDL), measured or reported diabetes status
(yes/no), and current treatment for raised blood pressure
(yes/no). In model 2, we used the same variables as the
laboratory-based model (model 1) except HDL (same as
WHO/ISH with cholesterol risk) and in model 3 we ex-
cluded TC and HDL (same as WHO/ISH without chol-
esterol risk). In model 4 we used the same risk factors as
in model 1 but replaced TC and HDL with ABSI as an
anthropometric indicator. This could be a unique model
for NB-NCDP as we replaced anthropometric indicator
based on maximum strength of association with CHD
from our data set.
Ethical consideration
The present study was carried out according to the
guidelines laid down in the Declaration of Helsinki on
medical ethics. All participants provided verbal consent
in presence of witness [23] and the NB-NCDP study was
approved by the Human Research Ethics Committee
(HREC) of the University of New South Wales (HREC
ref: ≠HC12621), Sydney, Australia and the Ethics Review
Committee of the Diabetic Association of Bangladesh
(BADAS).
Ascertainment of cases (Outcome assessment)
To identify cases, history of chest pain indicating cardio-
vascular problems (diagnosed by a set of questions, ap-
proved by WHO CVD-risk management package for
low- and medium – resource settings’ for CVD scree-
ning) [19], were collected and ECG was performed in
suspected cases. To be identified as an MI case for over-
all CHDs, the participants need to fulfil two criteria, a)
symptoms of cardiac ischaemia and b) development of
unequivocal pathological Q wave in the ECG [24]. Per-
sons already diagnosed with MI by physician during the
follow–up period were also considered as cases.
Statistical analysis of case-cohort data
Descriptive statistics of demographic and other variables
were reported separately for cases and non-cases in the
study as well as by gender. Independent samples t-test
and chi-squared test were conducted for continuous and
categorical variables respectively for between group
comparisons.
The end point in this study was defined as myocardial
infarction (MI) evidenced from ECG abnormality. To
estimate risk we fitted the Cox proportional hazards
model to the calculation hazard ratio for developing
CHD (i.e., MI).
Before fitting Cox models we appropriately created the
analytical dataset from case-cohort design. For each sub-
ject in the case-cohort study, follow-up time was split
into two parts, the time before the exit time and the exit
time. Each non-failure from the sub-cohort contributes
one line of data to the analytic data set as censored ob-
servations. Failures from the main cohort contribute no
information prior to their failure times. Thus, they con-
tribute one line of data to the analytic data set as failures
but only at their failure times. This is because of the as-
sumption that failures outside the sub-cohort occur just
after entering the subject into the study [25]. Failures
from the sub-cohort contribute two lines to the analytic
data set: as a censored observation prior to their failure
times and as a failure at their failure time. To create a
time “just before the exit time,” an amount (0.0001) less
than the precision of exit times given in the data was
subtracted from the actual failure time [26]. The robust
standard error was estimated using “COVSANDWICH
(aggregate)” option in SAS. From the fitted model we
predicted absolute failure risk for each observation in
our dataset. From the predicted risk we calculated the
C-statistic and generated receiver operator characteristic
(ROC) curves for each of the four models separately by
gender. The C-statistic was calculated and compared
across different models using the roccomp command in
STATA version 13. Smoothed ROC curves were gener-
ated using PROC SGPLOT in SAS to distinguish the
curves for different models. All the regression analyses
were conducted separately for males and females.
We used SAS version 9.4 for fitting the Cox models as
described in Langholza & Jiaob (2007) [26].
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The predictive power of those four models was com-
pared using C-statistic and ROC curves. We also calcu-
lated sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV) and the percent-
age correctly classified for this purpose. These parameters
were calculated by using four different cut-off values
(5 %, 10 %, 20 % and 30 %) of the predicted absolute risk.
We also calculated the “Net Benefit Fraction (NBF)”,
defined as (TP −w × FP)/N, where TP is the number of
true-positive decisions, FP is the number of false-
positive decisions, N is the total number of the popula-
tion, and w is a weight equal to the odds of the thresh-
old (P treatment/(1 − P treatment)). This is considered
as the harm/benefit ratio of treatment; for example, at
the threshold of 10 %, the FP is valued at one-ninth of
the TP [27]. Because the maximum net benefit equals
the incidence rate of disease [28], given that all events
are TP with no FP, we divided net benefit by the inci-
dence rate. In this way, we defined the net benefit frac-
tion as a simple relative utility index [29], which is the
fraction of the incidence rate that could be predicted
and prevented, appropriately regarding the usefulness of
treatment for true positives and a negative weight for
harmfulness of treatment in false positives.
Statistical analyses were performed by using SPSS for
Windows, version 22 (SPSS, Inc., Chicago, Illinois),
Stata, version 13 (StataCorp LP, College Station, Texas)
statistical software and SAS. Two-sided P < 0.05 was
considered statistically significant.
Results
The follow-up time ranged from 24–29 months
(2—2.5 years, based on starting date of the follow-up of
the sub-cohort and the date of ECG assessment) with a
minimum of 2 years. The median follow-up time was
814 days with a range of 770 to 851 days. There were 60
incident cases of MI during this study follow-up period of
2.5 years. These 60 cases were generated from a total
follow-up of 156337.5 person years (including 6 non-CVD
related deaths) which translates in to an incidence rate of
38.38 cases per 100,000 person years. The overall charac-
teristics of the population are listed in Table 1. By design,
the NB-NCDP cohort was representative of the adult rural
population in Bangladesh. Most participants were in
middle age, mean age ± SD was 53.73 ± 10.71 years. The
majority had no or only primary school education, poor
vegetable and fruits intake, one third of participants were
under weight and the majority had abnormal HDL. Over-
all, with the exception of a higher number of female cases
(p < 0.016), higher rates of elevated DBP (p < 0.017), pre-
HTN and HTN (p < 0.043) for cases, the CVD risk distri-
bution was similar between controls and cases. The 54
deaths due to cardiovascular disease represented 2.58 % of
all deaths in the cohort (Fig. 1).
Table 2 shows summary statistics for risk factors used
in risk models. Female participants were, on average, five
years younger than males and had a higher rate of ab-
normal total cholesterol. On contrary, males had higher
smoking and BP treatment rates. The remaining risk fac-
tors were similar between the sexes.
Table 3 shows hazard ratio with 95 % confidence
interval and p values from the Cox regression models
predicting cardiovascular disease events by sex. All four
predictive models (i.e., model 1, model 2, model 3 and
model 4) showed almost similar pattern with risk distri-
bution. It showed that systolic blood pressure and dysli-
pidaemia (i.e., TC and HDL) for men in all four models
and ABSI for women in model 4 was significant. In
women, model 4 showed fair predictive power, with a c
statistic (95 % CI) of 0.685 (0.581–0.789). The C-
statistic of model 1, 2 and 3 were 0.634 (0.526–0.741);
0.626 (0.521–0.731) and 0.611 (0.506–0.717) respect-
ively. The four c statistics were not significantly differ-
ent (χ2 = 1.08, with 3 DF P = 0.7814). In men, the C-
statistic for model 1 was 0.675 (0.575–0.775) and for
model 2, 3 and 4 were 0.644 (0.541–0.747), 0.631
(0.528–0.734) and 0.627 (0.525–0.728) respectively.
They were also not significantly different (χ2 = 0.54,
with 3 DF P = 0.9092).
The ROC curves show a large amount of overlap in
the predictive discrimination of the four models for both
women and men. Adding ABSI to the non-laboratory-
based model instead of total cholesterol did not improve
the predictive discrimination in either sex (Fig. 2).
An ECG-based definition of cardiovascular disease,
that included only MI cases, was used, but the difference
between the four models remained small with narrower
endpoints. The analysis with cardiovascular deaths only,
where the possibility of misclassification is kept to a
minimum, resulted in C-statistics of 0.675, 0.644, 0.631
and 0.627 for model 1–4 respectively in the men, with
similar results for women. These C-statistics were not
significantly different.
The predictive discrimination of all four models
against the various screening test characteristics is
shown in Table 4. There was no significant difference
in any of the characteristics between the four models at
each of the risk thresholds tested for women or men.
The sensitivity and specificity of both tests were also
similar for each model at each risk threshold. Sensitivity
was in between 65–69 % (men) and 84–90 % (women)
at the lowest threshold (5 %, 2.5-year risk) and less than
29 % for women and 21 % for men at the highest
threshold (30 %, 2.5-year risk). Considering all four
models, among men, only 11 % developed CVD events
during follow-up (positive predictive value, PPV),
whereas, of those categorised at low-risk level, 92 %
remained event free during the follow-up (negative
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Table 1 Distribution of socio demographic, behavioral, anthropometric, clinical and biochemical characteristics of the study
participants
Variablesa Disease freeb (n = 394) Total casesb (n = 60) P valuec
Gender
Male 258 (65.5) 29 (48.3) 0.010
Female 136 (34.6) 31 (51.7)
Age (years) (M ± SD) 53.73 ± 10.71 53.90 ± 10.75 0.909
31–45 115 (29.2) 19 (31.7) 0.927
46–60 180 (45.7) 25 (41.7)
61 yrs & above 99 (25.1) 16 (26.7)
Education
None or Primary 296 (75.1) 52 (86.7) <0.001
Secondary level and above 98 (24.9) 8 (13.3)
Gross National Income (per capita, US$)
Low income (≤905) 204 (51.8) 30 (50.0) 0.858
Lower-middle income (906–3595) 190 (48.2) 30 (50.0)
Employment status
Unemployed/sacked from the present job/Retired/House maker/farmer 236 (59.9) 39 (65.0) 0.448
Office work/Business/Skilled labour/Rickshaw puller/day labour/Others 158 (40.1) 21 (35.0)
Behavioral risk factors
Smoking Pattern
Non-smoker 276 (70.1) 45 (75.0) 0.543
Smoker 118 (29.9) 15 (25.0)
Smokeless tobacco
Non smokeless tobacco 242 (61.4) 46 (76.7) 0.022
Regular smokeless tobacco 152 (38.6) 14 (23.3)
Fruits intake pattern
Less than 1 servings/day 393 (99.7) 60.0 (100) 0.594
1–2 servings/day 1 (0.3) -
Vegetables intake pattern
Less than 2 servings/day 205 (52.0) 39 (65.0) 0.071
3–5 servings/day 189 (48.0) 21 (35.0)
Anthropometric risk factors
BMI (M ± SD) 20.0 ± 3.6 19.6 ± 3.3 0.298
Underweight (BMI < 18.5) 139 (35.3) 25 (41.7) 0.256
Normal (18.51–23.0) 176 (44.7) 26 (43.3)
Overweight and obese (>23.0) 79 (20.1) 9 (15.0)
Waist circumference 80.46 ± 10.0 81.5 ± 10.9 0.489
Normal (<0.90 male, <0.80 female) 300 (76.1) 37 (61.7) 0.021
High risk (>0.90 male, >0.80 female) 94 (23.9) 23 (38.3)
Waist Hip Ratio 0.93 ± 0.06 0.92 ± 0.06 0.916
Normal (<0.95 male, <0.80 female) 185 (47.1) 22 (36.7) 0.065
Moderate (0.96–1.0 male, 0.81–0.85 female) 57 (14.5) 7 (11.7)
High risk (>1.0 male, >0.85 female) 151 (38.4) 31 (51.7)
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predictive value, NPV). On the other hand, among
women PPV was 20 % and NPV was 90 %. When the
threshold was greater than 30 %, the positive predictive
value for all models was roughly 18 % and 11 % and the
negative predictive value greater than 81 % and 90 %
for women and men respectively. The results for the al-
ternative analysis using the threshold of 10 % and 20 %
are shown in Table 4.
Table 1 Distribution of socio demographic, behavioral, anthropometric, clinical and biochemical characteristics of the study
participants (Continued)
Waist Height Ratio 0.51 ± 0.06 0.52 ± 0.07 0.404
<=0.5 (non central fat distribution - pears) 195 (49.5) 26 (43.3) 0.375
>0.5 (central fat distribution - apples) 199 (50.5) 34 (56.7)
ABSI (m11/6/kg2/3) (M ± SD) 0.0868 ± 0.0065 0.0895 ± 0.0070 0.003
Clinical and biochemical risk factors
Systolic blood pressure (mmHg) 115 ± 31 119 ± 24 0.273
Normal (≤140 mmHg) 375 (95.2) 57 (95.0) 0.394
High (≥140 mmHg) 19 (4.8) 3 (5.0)
Diastolic blood pressure (mmHg) 73 ± 14 77 ± 13 0.55
Normal (≤90 mmHg) 384 (97.5) 52 (86.7) 0.017
High (≥90 mmHg) 10 (2.5) 8 (13.3)
Hypertension
Normotensive 340 (86.3) 47 (78.3) 0.043
Pre-hypertensive 49 (12.4) 10 (16.7)
Hypertensive 5 (1.3) 3 (5.0)
Biochemical risk factors
Fasting blood glucose (mmol/l) 4.44 ± 1.25 4.53 ± 1.02 0.555
2 hrs after 75gm glucose (mmol/l) 6.76 ± 2.09 6.83 ± 2.66 0.855
Glycemic Status
Non diabetic 280 (81.6) 43 (76.8) 0.368
Pre-diabetic 55 (16.0) 11 (19.6)
Diabetic 8 (2.3) 2 (3.6)
Cholesterol (mg/dl) 179 ± 44 179 ± 53 0.975
<200 normal 265 (75.9) 48 (85.7) 0.427
200.01–240 border line high 56 (16.0) 2 (3.6)
>240.01 high 28 (8.0) 6 (10.7)
Triglyceride (mg/dl) 145 ± 100 145 ± 67 0.991
<150 normal 242 (69.2) 39 (69.6) 0.787
150.01–200 border line high 61 (17.5) 11 (19.6)
>200.01 high 46 (13.2) 6 (10.7)
HDL (mg/dl) 38 ± 10 37 ± 8 0.219
Normal (male >40, Female >50) 14 (4.0) 1 (1.8) 0.705
Risk (male < 40, Female < 50) 335 (96.0) 55 (98.2)
LDL (mg/dl) 114 ± 31 114 ± 44 0.997
Normal (LDL < 100) 135 (38.8) 23 (41.1) 0.879
Near normal (LDL ≥ 100.01 & < 130) 123 (35.3) 21 (37.5)
High (LDL ≥ 130.01 & < 190) 82 (23.6) 8 (14.3)
Very high (LDL > 190.01) 8 (2.3) 4 (7.1)
aValues expressed as numbers and percentages in parentheses or mean ± SD, as appropriate; SD, standard deviation; yrs, years; bAll the disease free participants
came only from the sub-cohorts but the cases came from both the main and sub-cohorts; cFor continuous variables p-values were obtained by doing independent
samples t-test and for categorical variable from chi-squared test; Significance between normal and total cases
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From a clinical performance view point, all models
have nearly the same net benefit fraction [14 % for
women and 5.0 % for men] at lowest threshold (5 %).
The net benefit fractions were 13.9 %, 14.5 %, 14.1 %
and 13.5 %; 4.8 %, 5.1 %, 4.8 % and 5.2 % of the inci-
dence of women and men, and model 1, 2 3 and 4 re-
spectively at 5 % threshold level. For higher threshold,
NBF values are truly low or negative. Due to the low
predictive power of the models the curve showed a poor
net benefit at the lowest threshold (<5 %) with respect to
the different predictive models over the whole range of
values. The curve performances were worse in men
(results are not shown here).
Discussion
The present data show that short-term (2.5 years)
predictive discrimination values of the models do not
differ significantly among them within either sex. All
models have quite good NPVs but poor PPVs. The
non-laboratory based models (e.g., model 3 and 4),
that used easily obtainable information from any par-
ticipant even from a single outpatient visit, can pre-
dict CVD outcomes with the same degree of accuracy
as the laboratory-based tools that require HDL and/or
total cholesterol and thus become expensive and diffi-
cult to be applied in some settings. From the overall
analysis the newly proposed non-lab based model
(which includes ABSI, a new anthropometric indica-
tor) showed better performance in women.
These study findings indicate a quite high performance
of all the four prediction tools in identifying subjects
who will not develop CHD on a short-term (around
2.5 years) basis. The conclusion is based on the 84 % to
92 % NPVs with various models at different threshold
levels. It should be noted that the sensitivity and specifi-
city of the different tools vary considerably depending
Fig. 1 Case cohort follow up profile
Table 2 Summary statistics for risk factors used in risk models
(All cases identified from main cohort and all participants from
sub-cohort)
Characteristics aWomen (n = 167) bMen (n = 287)
Age, mean (SD), y 50.8 (10.4) 55.5 (10.5)
Total-C, mean (SD), mg/dl 178.9 (56.2) 178.9 (39.3)
HDL-C, mean (SD), mg/dl 37.2 (8.8) 38.0 (10.1)
Systolic BP, mean (SD), mm Hg 113.4 (23.2) 115.0 (20.9)
BP treatment, n (%) 14 (8.4) 27 (9.4)
Smoking, n (%) 23 (13.8) 110 (38.3)
Diabetes, n (%) 21 (12.6) 57 (19.9)
ABSI (m11/6/kg2/3), mean (SD) 0.0893 (0.0069) 0.859 (0062)
aamong women, 22 cases from main cohort and 9 cases from the sub-cohort
bamong men, 20 cases from main cohort and 9 cases from the sub-cohort
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on the risk threshold chosen. Generally, the sensitivity is
seen to decrease with increasing risk threshold while
specificity behaves in the opposite manner. In contrast
to sensitivity and specificity, the NPV varies little be-
tween the tools at any given risk threshold levels. There
is still debate at which threshold level of CVD risk a
clinical intervention should be made [30]. Some authors
suggest a cut-off value of 20 % [3], but a cut-off value as
low as 5 % has also been suggested [31]. A consistent
NPV irrespective of the threshold levels will be helpful
for the clinical decision making process. The ability of
the present models in identifying the true negative (i.e.
not to be treated) subjects could be useful to the
clinicians in the context of the prevailing practices regar-
ding CVDs. Based on individual risk factor analysis, over-
treatment has been reported to be an equal problem to
under-treatment among persons with CVD risk factors
[32]. In Bangladesh, although there is not yet any pub-
lished study, from empirical experience and from personal
communication with a few practicing cardiologists in
Dhaka it seems that over-treatment is an equal (if not
greater) problem compared to under-treatment due to un-
regulated clinical practices (even by unqualified practi-
tioners) and aggressive marketing of drugs. Accordingly, a
fairly accurate decision on non-intervention has a positive
contribution on an individual as well as population levels.
Table 3 Hazard ratios of CHD (only MI) from multivariable Cox proportional hazards model
Variable Women Men
HR 95 % CI P HR 95 % CI P
Model 1 (Laboratory based)a
Age (in 10 yrs) 0.99 0.71–1.38 0.968 1.38 0.97–1.98 0.078
Total cholesterol (mg/dl in 10 yrs) 0.99 0.88–1.12 0.930 1.13 1.03–1.26 0.015
HDL cholesterol (mg/dl in 10 yrs) 0.77 0.39–1.53 0.455 0.50 0.26–0.98 0.042
Systolic blood pressure (mm Hg in 10 yrs) 1.18 0.96–1.55 1.452 1.52 1.23–1.89 0.0001
History of blood pressure treatment 0.78 0.15–3.99 0.763 1.54 0.45–5.30 0.490
Current smoker 0.77 0.27–2.23 0.628 1.88 0.93–3.81 0.081
Diabetes 1.22 0.46–3.26 0.694 1.34 0.61–2.9 0.466
Model 2 (WHO with cholesterol)b
Age (in 10 yrs) 1.10 0.70–1.73 0.683 1.39 0.87–2.21 0.168
Total cholesterol (mg/dl in 10 yrs) 0.97 0.87–1.08 0.614 1.01 0.89–1.15 0.878
Systolic blood pressure (mm Hg in 10 yrs) 1.21 0.91–1.61 0.187 1.62 1.22–2.15 0.0008
History of blood pressure treatment 0.80 0.16–3.92 0.781 1.80 0.51–6.31 0.357
Current smoker 0.53 0.11–2.64 0.437 1.54 0.61–3.93 0.363
Diabetes 1.58 0.47–5.23 0.455 1.37 0.51–3.70 0.534
Model 3 (WHO without cholesterol)c
Age (in 10 yrs) 1.05 0.67–1.63 0.833 1.45 0.90–2.34 0.123
Systolic blood pressure (mm Hg in 10 yrs) 1.11 0.76–1.62 0.606 1.77 1.35–2.32 <0.0001
History of blood pressure treatment 0.44 0.06–3.10 0.412 1.94 0.48–7.82 0.348
Current smoker 0.52 0.11–2.56 0.421 1.56 0.61–3.98 0.353
Diabetes 1.44 0.43–4.83 0.556 1.41 0.53–3.78 0.488
Model 4 (Non-laboratory based)d
Age (in 10 yrs) 0.83 0.51–1.34 0.448 1.36 0.89–2.08 0.149
Systolic blood pressure (mm Hg in 10 yrs) 1.13 0.86–1.48 0.392 1.57 1.21–2.04 0.0007
History of blood pressure treatment 1.65 0.36–7.51 0.516 1.79 0.51–6.28 0.369
Current smoker 0.84 0.21–3.41 0.827 1.74 0.78–3.87 0.175
Diabetes 0.88 0.27–2.84 0.827 1.16 0.46–2.90 0.754
ABSIe (from 1 SD) 3.20 1.60–6.42 0.001 1.09 0.53–2.22 0.817
HR hazard ration, yrs years, SD standard deviation
aC statistics (95 % CI): 0.634 (0.527–0.710) for women; 0.675 (0.575–0.775) for men
bC statistics (95 % CI): 0.626 (0.521–0.731) for women; 0.644 (0.541–0.746) for men
cC statistics (95 % CI): 0.611 (0.506–0.717) for women; 0.631 (0.528–0.734) for men
dC statistics (95 % CI): 0.685 (0.581–0.789) for women; 0.627 (0.525–0.728) for men
eABSI (1 ± SD, male 0.0062 and female 0.0069)
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On the contrary to NPV, the PPVs of the present tools
are remarkably low and they vary between men (around
10 %) and women (around 20 %). Like NPV, the values are
fairly stable at various risk threshold levels. The perfor-
mances of the tools, thus, are poor in identifying the true
positive cases (i.e., subjects who should have medical treat-
ment to reduce the chance of progression to CHDs). Again,
the PPVs do not vary among the four models (Table 4).
The best method for analysing and reporting the per-
formance of risk prediction tools in order to guide clin-
ical decision making is still a subject of debate in the
literature. Various authors have proposed NBF [27, 30]
and decision curve analysis [28, 30] as alternate pro-
cedures in this respect. Until the suitability of these
suggestions is fully established, application of the tra-
ditional views regarding PPV and NPV (based on clinical
and economic benefit/harm of an intervention) should
be continued. A close look at the findings of the present
study shows that the clinicians will have an additional
benefit for around 10 % of male and 20 % of female
cases regarding the initiation of treatment; in the
remaining cases, they will need to decide on their own
judgment based on individual risk factors. However, the
current prediction models have good NPV values and
therefore may assist clinical decision making on which
individuals do not require risk factor treatment beyond
lifestyle advices. A unique situation with CVD risk fac-
tors is that all subjects with CVD risk are strongly advised
Fig 2 ROC curves for men (top) and women (bottom) for model 1 (laboratory-based), model 2 (WHO/ISH with cholesterol) and model 3
(WHO/ISH without cholesterol) and model 4 (non-laboratory-based) methods for prediction of cardiovascular disease (based on maximum
2.5 months observation period)
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Table 4 Predictive discrimination of four models at different cut off values of cardiovascular risk thresholds over 2.5-year of follow-up
Cut-off values 5 % 10 % 20 % 30 %
Women
Sensitivity (95 % CI)
Model 1 87.1 (70.2–96.4) 71.0 (52.0–85.8) 54.8 (36.0–72.7) 41.9 (24.5–60.9)
Model 2 90.3 (74.2–98.0) 67.7 (48.6–83.3) 48.4 (30.2–66.9) 35.5 (19.2–54.6)
Model 3 87.1 (70.2–96.4) 71.0 (52.0–85.8) 45.2 (27.3–64.0) 29.0 (14.2–48.0)
Model 4 83.9 (66.3–94.5) 77.4 (58.9–90.4) 54.8 (36.0–72.7) 38.7 (21.8–57.8)
Specificity (95 % CI)
Model 1 24.7 (17.9–32.5) 40.4 (32.4–48.8) 57.5 (49.1–65.7) 69.9 (61.7–77.2)
Model 2 24.8 (17.3–31.7) 42.5 (34.3–50.9) 53.4 (45.0–61.7) 67.1 (58.9–74.7)
Model 3 28.1 (21.0–36.1) 38.4 (30.4–46.8) 53.4 (45.0–61.7) 65.8 (57.5–73.4)
Model 4 29.5 (22.2–37.6) 43.2 (35.0–51.6) 61.0 (52.5–68.9) 70.5 (62.5–77.8)
Positive predictive value (95 % CI)
Model 1 19.7 (13.4–27.4) 20.2 (13.1–28.9) 21.5 (13.1–32.2) 22.8 (12.7–35.8)
Model 2 20.1 (13.8–27.8) 20.2 (12.8–28.9) 18.1 (10.5–28.0) 18.6 (9.7–30.9)
Model 3 20.5 (13.9–28.3) 19.6 (12.7–28.2) 17.1 (9.7–27.0) 15.3 (7.2–27.0)
Model 4 20.2 (13.6–28.1) 22.4 (14.9–31.5) 23.0 (14.0–34.2) 21.8 (11.8–35.0)
Negative predictive value (95 % CI)
Model 1 90.0 (76.3–97.2) 86.8 (76.4–93.8) 85.7 (77.2–92.0) 85.0 (77.3–90.9)
Model 2 92.1 (78.6–98.3) 86.1 (75.9–93.1) 83.0 (73.8–89.9) 83.1 (75.0–89.3)
Model 3 91.1 (78.8–97.5) 86.2 (75.3–93.5) 82.1 (72.9–89.2) 81.4 (73.1–87.9)
Model 4 89.6 (77.3–96.5) 90.0 (80.5–95.9) 86.4 (78.2–92.4) 84.4 (76.8–90.4)
Men
Sensitivity (95 % CI)
Model 1 65.5 (45.7–82.1) 51.7 (32.5–70.6) 34.5 (17.9–54.3) 24.1 (10.3–43.5)
Model 2 69.0 (49.2–84.7) 51.7 (32.5–70.6) 31.0 (15.3–50.8) 20.7 (8.0–39.7)
Model 3 69.0 (49.2–84.7) 58.6 (38.9–76.5) 24.1 (10.3–43.5) 20.7 (8.0–39.7)
Model 4 72.4 (32.1–43.9) 51.7 (32.5–70.6) 24.1 (10.3–43.5) 24.1 (10.3–43.5)
Specificity (95 % CI)
Model 1 44.1 (45.7–82.1) 58.8 (52.7–64.7) 73.2 (67.5–78.3) 79.8 (74.5–84.4)
Model 2 41.5 (35.6–47.6) 54.0 (47.9–60.1) 72.1 (66.3–77.3) 82.4 (77.3–86.7)
Model 3 38.6 (32.8–44.7) 53.7 (47.6–59.7) 73.2 (67.5–78.3) 83.1 (78.1–87.3)
Model 4 37.9 (32.1–43.9) 52.9 (46.8–59.0) 72.1 (66.3–77.3) 81.3 (76.1–85.7)
Positive predictive value (95 % CI)
Model 1 11.1 (6.8–16.8) 11.8 (6.8–18.7) 12.0 (5.9–21.0) 11.3 (4.7–21.9)
Model 2 11.2 (7.0–16.7) 10.7 (6.1–17.1) 10.6 (5.0–19.2) 11.1 (4.2–22.6)
Model 3 10.7 (6.7–16.0) 11.9 (7.1–18.4) 8.8 (3.6–17.2) 11.5 (4.4–23.4)
Model 4 11.1 (7.0–16.4) 9.9 (5.5–16.0) 8.4 (3.5–16.6) 12.1 (5.0–23.3)
Negative predictive value (95 % CI)
Model 1 92.3 (86.3–96.2) 92.0 (86.9–95.5) 91.3 (86.7–94.7) 90.8 (86.4–94.1)
Model 2 92.6 (86.5–96.6) 91.3 (85.8–95.2) 90.7 (86.1–94.3) 90.7 (86.4–94.0)
Model 3 92.1 (85.5–96.3) 92.4 (87.1–96.0) 90.0 (85.3–93.7) 90.8 (86.5–94.1)
Model 4 92.8 (86.3–96.8) 90.6 (84.9–94.6) 89.9 (85.1–93.6) 90.9 (86.6–94.2)
Abbreviations: CI confidence interval; Model 1, Laboratory based model same as Framingham Risk Score; Model 2, Non laboratory based model; Model 3, WHO/ISH
with Cholesterol; Model 4, WHO/ISH without Cholesterol
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to pursue healthy nutritional habits and lifestyle. Accord-
ingly, whatever decision is made by the clinicians based
on PPV and/or NPV, all subjects are advised to pursue
practices which potentially prevent CVDs. In addition to
clinical settings, public health programs are increasingly
promoting healthier nutrition and lifestyle to reduce the
risk of CVDs and thus subjects not requiring clinical
intervention based on absolute risk assessment should
still be exposed to health promotion messages.
It is worthwhile to note that the predictive performance
of the non-laboratory-based models (3 & 4) did not vary
from those of the laboratory-based ones (model 1 & 2).
For women, model 4 (the Framingham adapted new
model in NB-NCDP) had a higher C-index (95 % CI) of
0.685 (0.581–0.789) compared to the other three models
[0.634 (0.526–0.741); 0.626 (0.521–0.731) and 0.611
(0.506–0.717) for model 1, 2 and 3 respectively], although
the differences are not statistically significant (p = 0.7814
in men and 0.9092 in women). Model 4 also had a higher
NPV in women. It is interesting to note that, in the Cox
model, hazard ratios showed that BP (p < 0.001) and lipid
profile (p < 0.015) are consistently associated with CHD
outcome in men, but in women the association is shifted
to ABSI (<0.0001). Inclusion of ABSI in the model may
be the underlying reason for the higher C-index as well
as NPV obtained with this tool.
The strengths of the current study include its case-
cohort design and use of appropriate analytical tech-
niques (e.g., calculation of C-statistics from a Cox
model) taking into consideration of the subtlety in the
study design. Inclusion of detailed follow-up data and
availability of major anthropometric and other trad-
itional cardiovascular risk factors were additional
strengths of this study. These facilitated the independent
comparison of different anthropometric findings to iden-
tify the best measure associated with CHD. Although
use of ECG has increased the objectivity in diagnosing
CHD, a major limitation in this study is that only CHD
has been used as a marker of CVDs. In one study 85 %
of the CVDs reported were ascribed to CHDs [30]. Still
exclusion of non-CHD CVDs may be one reason for
which we have a very low incidence rate of CVD cases
compared to other studies that included MI and other
cardiovascular events. A comprehensive clinical assess-
ment by clinicians was not done during data collection
in this study which might detect some CVDs other than
MIs. In the absence of any evidence from the present
population, it is difficult to ascertain the degree of con-
formity of the present findings with the overall incidence
of CVD events. It is quite likely that we have underesti-
mated the true rate. It is also possible that we have
underestimated the incidence of CHD as only those par-
ticipants with clinical and ECG features of myocardial
infarction were included as cases. Another limitation is
that, like other studies [3, 33], we used total cholesterol
and HDL, but the lab-based studies did not improve pre-
dictive performance of the models (i.e., model 1 & 2)
over the non-lab-based ones (models 3 & 4). The C-
statistics of both laboratory-based and non-laboratory-
based models in prediction of CVD were <0.70, though
there was some outcome misclassification which is inde-
pendent of the explanatory variable that would give a
non-differential error. That error would pull the associ-
ation towards null, which in turn, would jeopardise the
predictive power of the models. Moreover, the small
number of cases in the cohort also could be a reason of
non-significant association with the known risk factors.
Our sample size calculation was based on the minimum
requirement of 5 cases per explanatory variables in the
predictive model. We had only 29 cases in males and 31
in females. Thus, the total sample size was minimum for
Model 2, 3 and 4, and less than required for Model 1
which limits the ability to test the performance of clin-
ical prediction of these four models in this setting. How-
ever, even if the laboratory-based model was marginally
improved (by C-statistics, over non-lab model), it is still
an open question whether the additional benefit would
be justified in the context of resource limited developing
settings considering the involvement of additional cost
and logistics.
Conclusion
In conclusion, ‘Not to be treated for CVD risk’ cases,
may be identified with fairly good confidence by using
the most commonly used CVD risk prediction tools
based on short-term prediction. A newly proposed non-
laboratory-based tool, using the overall obesity marker
ABSI as a key variable, seems to be an alternate with
equal performance in men and slightly better perform-
ance in women. It would be worthwhile to follow the co-
hort for exploring and comparing the predictive ability
of these four models regarding CVD outcome in the lon-
ger term.
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